STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GSK acquired global rights to a preclinical multiple myeloma treatment from China's Chimagen Biosciences for up to $750 million, citing improved safety over existing T-cell engagers that have had "difficult tolerability profiles."
- The Chimagen Biosciences candidate, which GSK calls a "potential first-in-class" trispecific T-cell engager, remains in preclinical development and is slated to begin human testing next year.
- FDA convened a four-hour public meeting Monday where doctors, veterans, pharmacists, and therapists urged the agency to establish clear safety and access standards for psychedelic therapies.
- The psychedelic discussion covered provider training, patient screening and monitoring, access, reimbursement, clinic capacity, and long-term safety data collection, part of the Trump administration's months-long push to bring qualified psychedelic drug programs to market.
Why it matters: GSK committed up to $750 million for global rights to a preclinical-stage multiple myeloma drug from China's Chimagen Biosciences that won't enter human trials until next year, locking in years of clinical risk on an unvalidated asset. Separately, the Trump administration's months-long push for psychedelic therapy delivery standards signals regulatory energy is shifting from efficacy questions to how treatments will actually be rolled out in clinics.
Ask SkimNews
